BiotechTube
Home/Pipeline/GS1191

GS1191

Hemophilia A

Phase 1Active

Key Facts

Indication
Hemophilia A
Phase
Phase 1
Status
Active
Company
Gritgen Therapeutics

About Gritgen Therapeutics

A Chinese gene therapy biotech developing next-generation AAV-based treatments for rare and common diseases, with a lead hemophilia A program in Phase I trials.

View full company profile

Therapeutic Areas

HematologyRare DiseaseGenetics

Other Hemophilia A Drugs

DrugCompanyPhase
FVIII-GMACCellGenTechPreclinical
BIVV001 (rFVIIIFc-VWF-XTEN)Swedish Orphan BiovitrumPhase 3
Coagulation Factor VIIIShanghai RAAS Blood ProductsMarketed
Human Coagulation Factor VIIIHualan Biological EngineeringMarketed
Giroctocogene fitelparvovec (SB-525)Sangamo TherapeuticsPhase 3